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microscopy. The tumor cells stained positive for actin, desmin, and
vimentin but negative for pancytokeratin, S100, CD4, CD31,
UEA, and factor VIII. Chromosome analyses from peripheral
lymphocytes of the index case revealed a structurally abnormal Y-
chromosome (paracentric inversion Yq?) and gonosomal aneu-
ploidy: 45,X(1)/46,XY(34)/47,XXY(1)/47,XYY(3). In two me-
taphases a pericentric inversion (12)(p13.3q13) was present. The
breakpoints concern regions of three proto-oncogenes (HST2,
HER3, WNT1). Analyses of Y-speci®c sequences in the genomic
DNA of the patient (SY 14, 70, 78, 85, 132, 156, 160) has revealed
no Y-deletion thus far. Disruption of a gene by the suspected
paracentric inversion Yq cannot be excluded. Further molecular
studies are in progress. Conventional chromosome analyses of one
tumor revealed, in addition to the structurally abnormal Y-
chromosome, a clonal 1; 6 translocation t (1; 6)(q25:q25). Coupling
analyses in the family have not been performed thus far because of
lack of cooperation.
In summary, the presented pedigree is unique as it shows an
exclusive male-to-male transmission of hereditary glomus tumors.
Our ®ndings also suggest a causal involvement of a structurally
abnormal Y-chromosome.
Immunophenotypical characterization of the glomus cells was enabled by Dr. W.
Weninger, Univ.-Dept. of Dermatology, Vienna, Austria.
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Leukaemia Inhibitory Factor (LIF) Expression in Skin from
Amyotrophic Lateral Sclerosis Patients Compared with Skin
from Normal Individuals: What is the Function of LIF in the
Skin?
To the Editor
We read with interest the recent paper by Hu et al (2000)
describing leukaemia inhibitory factor (LIF) expression in the skin
of patients with amyotrophic lateral sclerosis (ALS). To our
surprise, however, the authors recorded no or negligible LIF
immunoreactivity in their ``disease control'' skin (Fig 1, Hu et al,
2000) We also note that they used the skin of patients suffering
from other neurodegenerative disorders as controls for the ALS
patient skin. We do not think these are appropriate controls,
principally because they give the impression that normal undiseased
skin expresses little or no LIF.
Our group has conducted several studies recently on LIF
expression in normal skin and in a variety of in¯ammatory
disorders, using skin from normal individual donors as controls. We
always observed LIF immunoreactivity in normal skin, using the
standard avidin-biotin complex immunohistochemical method.
We have sampled skin from normal individuals both from surgical
patients receiving elective surgery and from punch biopsy of
normal volunteers. In the latter case, samples were dropped
immediately into formalin. In both cases, the results were the same.
A typical result is shown in Fig 1(A), using Fast Red B as
chromogen. Essentially the pattern of LIF staining in normal skin is
the same as reported by Hu et al for ALS skin. The immunostaining
for LIF is always cytoplasmic and was present in the epidermis only.
The lower layers of the epidermis, especially the basal layer, showed
weaker staining compared with the suprabasal epidermis and
corni®ed layers. Similar to Hu et al we found no LIF
immunostaining in the dermis (Fig 1A).
These results on normal skin are consistent and reproducible, not
only in our hands, but French investigators using both polyclonal
and monoclonal antibodies were also able to demonstrate a similar
pattern and intensity of LIF immunoreactivity in normal skin to
that which we had originally recorded.1
Furthermore we have used three different antibodies: rabbit
polyclonal IgG (R303 antibody from the Genetics Institute, Cam-
bridge, MA); rabbit polyclonal IgG (R&D Systems, Minneapolis,
MN), and rabbit polyclonal IgG (UBI, Lake Placid, NY) with the
same results (Paglia et al, 1996; Szepietowski et al, 1997). Our reverse
transcriptase±polymerase chain reaction analysis of normal skin shows
constitutive expression of LIF mRNA, both in vivo and in cultured
human keratinocytes (Paglia et al, 1996; Szepietowski et al, 1997). The
constitutive expression of LIF in normal skin is unusual, since
Figure 2. Multiple glomus tumors presenting as bluish painful
nodules (on the right forearm).
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normally cytokines are only made in traumatized tissue or on cell
stimulation. A notable exception is interleukin (IL)-1, which is
expressed in suprabasal layers of normal human epidermis (Didierjean
et al, 1989). We propose that LIF expression in normal skin may serve
as an early alarm system in the way that IL-1 appears to do. Damage to
the skin would release preformed LIF that could then stimulate IL-1
and IL-8 release from keratinocytes (Paglia et al, 1996), bringing in
host leukocytes to deal with infection.
We suggest an explanation as to why Hu et al did not ®nd LIF
immunostaining in their disease controls. The formalin ®xation
may have masked the LIF antigens to a greater degree in the thinner
disease control specimens. Did the authors try microwave or
protease antigen retrieval on the disease controls?
We believe that the mild proliferation (maximum, 40% over
controls) observed by Hu et al could be consistent with paracrine
stimulation due to IL-8 release from adjacent keratinocytes; IL-8
has been demonstrated to induce proliferation of keratinocytes
(Rennekampf et al, 2000) and LIF receptor expression has been
demonstrated in normal human keratinocytes (Paglia et al, 1996),
suggesting an autocrine stimulatory cytokine network. We have
shown that stimulation of keratinocytes with 10 ng per ml of LIF
protein induces a 4-fold increase in IL-8 (Paglia et al, 1996). None
the less, their results do suggest abnormal LIF expression in
neurologic disorders, which is consistent with our model (Paglia
et al, 1996) that the LIF protein may be an interface between the
immunologic and neural systems in the skin. Of interest in this
respect is that LIF expression is elevated in ALS epidermis, a disease
marked by loss of the glutamate transporter function (Rothstein
et al, 1995). Do defects in the metabolism of this excitatory
neurotransmitter induce LIF expression?
Despite our reservations about the choice of control tissue by Hu
et al, we ®nd their results most interesting, particular the fact that they
®nd that LIF induces a hyperproliferative state in keratinocytes. We
and others have recorded high levels of LIF mRNA expression in
other hyperproliferative diseases such as psoriasis (Bonifati et al, 1998)
and basal and squamous carcinomas (Szepietowski et al, 2001). We
found higher levels of LIF mRNA expression in lesional (but not
nonlesional) volar skin from psoriatic patients than in normal skin.2
We agree that the results of Hu et al show hyperproliferative effects of
LIF in ALS epidermis and higher expression of LIF compared with
skin from patients suffering other neurologic disorders. The
hyperproliferative effects of LIF on keratinocytes demonstrated by
Hu et al may also have relevance to the growth of keratinocyte stem
cells in the outermost layer of the hair follicle (Akiyama et al, 2000).
We noted high levels of LIF expression in a single cell layer of the
outermost part of the hair follicle (Paglia et al, 1996). Moreover, LIF
has been characterized as a stem cell growth factor in other cell systems
(reviewed in Gearing, 1993).
Regarding points made by Hu et al about LIF and in¯ammation,
we feel that it should be pointed out that in the majority of studies,
LIF was found to have pro-in¯ammatory activity. For example, LIF
injection into C3H/HeN mouse ear stimulates neutrophil in¯ux,
probably due to secondary induction of pro-in¯ammatory
cytokines (McKenzie et al, 1996). LIF treatment of cell cultures
induces IL-1, IL-6, and IL-8; cachexia is dramatically increased in
mice bearing LIF-expressing tumor; and septic shock and cancer
patients have high systemic circulatory levels of LIF (reviewed with
other studies demonstrating pro-in¯ammatory effects of LIF in
Alexander et al, 1994). These effects are consistent with the
reported role of LIF as a stimulator of the acute phase factor
(reviewed in Baumann and Gauldie, 1994). Banner et al (1998) is
the only study (in a mouse knock-out, not in normal skin) that
purports to show anti-in¯ammatory effects for LIF in the skin. We
feel the majority of data are consistent with a pro-in¯ammatory/
growth promotion function for LIF in the skin.
Roddie C. McKenzie, Jacek C. Szepietowski*
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*Department of Dermatology, University of Medicine,
Wroclaw, Poland
REFERENCES
Akiyama M, Smith LT, Shimizu H: Changing patterns of localization of putative stem
cells in developing human hair follicles. J Invest Dermatol 114:321±327, 2000
Alexander HR, Billingley KG, Block MI, et al: D-factor/leukemia inhibitory factor:
evidence for its role as a mediator in acute and chronic in¯ammatory disease.
Cytokine 6:589±596, 1994
BannerLR, Patterson PH, Allchorne A, et al: Leukemia inhibitory factor is an anti-
in¯ammatory and analgesic cytokine. J Neurosci 18:5456±5462, 1998
Baumann H, Gauldie J: The acute phase response. Immunol Today 15:74±80, 1994
Bonifati C, Mussi A, D'Auria L, et al: Spontaneous release of leukemia inhibitory
factor and oncostatin M is increased in supermatants of short term organ
cultures from psoriatic patients. Arch Dermatol Res 290:9±13, 1998
Didierjean L, Salmond D, Merot Y, et al: Localization and characterization. of the
Interleukin-1 immunoreactive pool (IL-1 alpha and beta forms) in normal
human epidermis. J Invest Dermatol 92:809±816, 1989
Gearing D: The leukemia inhibitory factor and its receptor. Adv Immunol 53:51±98,
1993
Hu J, Ono S, Katayama H, et al: Leukemia inhibitory factor induces epidermal
hyperplasia in patients with amyotrophic lateral sclerosis. J Invest Dermatol
115:486±492, 2000
McKenzie RC, Paglia D, Kondo S, et al: Leukemia inhibitory factor ± a novel mediator
of cutaneous in¯ammation. Acta Dermato-Venereol Stockh 76:114±114, 1996
Paglia D, Kondo S, Ng K-ME, et al: Leukaemia inhibitory factor is expressed by
normal keratinocytes in vitro and in vivo. Br J Dermatol 34:817±823, 1996
Rothstein JD, Van-Kammen M, Levey AI, et al: Selective loss of glial glutamate
transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38:73±84, 1995
Rennekampff HO, Hansbrough JF, Kiessig V, et al: Bioactive interleukin-8 is
expressed in wounds and enhances wound healing. J Surg Res 93:41±54, 2000
Szepietowski JC, McKenzie RC, Keohane SG, et al: Leukaemia inhibitory factor:
induction in the early phase of allergic contact dermatitis. Contact Dermatitis
36:21±25, 1997
Szepietowski JC, Walker C, Hunter JAA, et al: Leukemia inhibitory factor and
interleukin-8 expression in non-melanoma skin cancers. Clin Exp Dermatol 26:
in press, 2001
Figure 1. Immunostaining for LIF in normal skin. (A) LIF antibody
and ABC-HRP conjugate incubated with Fast Red B as substrate and
counterstained with hematoxylin; (B) negative control. Scale bar: 100 mM.
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